AbbVie just rewarded its shareholders again with a dividend. This stock has boosted its payout annually for more than 50 ...

UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ...

Korean firms pursue botulinum toxin market amid rising global demand Pharmaceutical companies capitalize on expanding ...

Casting is open. Allergan Aesthetics is on the search for women to inspire women as one of the Faces of Natrelle. The ...

It’s critical to understand what a digitally savvy HCP is in 2025 and what’s impeding pharma's communications with this ...

Vyalev is already available in the EU, where it has been approved under the Produodopa brand name since 2022. AbbVie held off on launch until it also got the green light from the European ...

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

Collectively, the top eight blockbuster drugs of 2024 generated over $116 billion in sales last year. Looking closer at these figures provides insight into the shifting landscape of the pharmaceutical ...

Evolus Inc . (NASDAQ:EOLS), a company specializing in aesthetic products with a market capitalization of $933 million, has recently made significant strides in expanding its product portfolio and ...

Tokyo, Japan and Cambridge, UK, 14 February 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the ...

ALS candidates from Biohaven, Prilenia, Clene and UCB have all failed to halt disease progression versus placebo in the US-wide platform trial.